

Amgen BLA STN 125518 Talimogene laherparepvec

The following officers or employees of FDA participated in the decision to approve this application and consented to be identified on this list.

FDAAA Section 916 (Action Packages)

Celia Witten, Director OCTGT	Consent
Stephanie Simek, Deputy Director, OCTGT	Consent
Mark L. Davidson, RPM, OCTGT	Consent
Ramjay Vatsan, Product Chairman, DCGT	Consent
Denise Gavin, Branch Chief, DCGT	Consent
Kimberly Benton, Deputy Director, DCGT	Consent
Michael Havert, Product DCGT	Consent
Andrew Byrnes, Product DCGT	Consent
Robert Aksamit, Product DCGT	Consent
Wilson Bryan, Director DCEPT	Consent
Ke Liu, Branch Chief DCEPT	Consent
Peter F. Bross, Team Leader DCEPT	Consent
Robert Q Le, Clinical DCEPT	Consent
Maura O’Leary, Clinical DCEPT	Consent
Chaohong Fan, Clinical DCEPT	Consent
Mercedes Serabian, Branch Chief Pharm/Tox DCEPT	Consent
Becky Robinson, Team Leader	Consent
Ying Huang, Pharm/Tox DCEPT	Consent
Boguang Zhen, OBE/DB	Consent
John Scott, Branch Chief, OBE/DB	Consent
Shiowjen Lee, Team Leader, OBE/DB	Consent
Abigail Luo, OBE/DB	Consent
Rabia Ballica, OCBQ/DMPQ	Consent
Deborah Trout, OCBQ/DMPQ	Consent
Nancy Waites, OCBQ/DMPQ	Consent
Christine Harman, OCBQ/DMPQ	Consent
Claire Wernly, OCBQ/DBSQC	Consent
Patricia Holobaugh, BIMO	Consent
Lillian Ortega, BIMO	Consent
Christopher Jankosky, Branch Chief OBE/DE	Consent
Meghna Alimchandani, OBE/ DE	Consent
Lisa Stockbridge, ABPL, Labeling	Consent
Loan Nguyen, ABPL, Labeling	Consent

Karen M. Campbell OCBQ/DBSQC/QAB
Josephine Resnick, OCBQ/DBSQC
James Kenney, OCBQ/DBSQC/LMIVTS
Hyesuk Kong, OCBQ/DBSQC/LMIVTS

Consent
Consent
Consent
Consent